121 results
8-K
EX-99.1
LQDA
Liquidia Corp
1 Apr 24
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
7:00am
believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives
S-8
LQDA
Liquidia Corp
13 Mar 24
Registration of securities for employees
4:34pm
”), of Liquidia Corporation (the “Registrant”) were automatically added to the shares authorized for issuance under the Liquidia Corporation 2020 Long-Term Incentive
S-8
EX-5.1
LQDA
Liquidia Corp
13 Mar 24
Registration of securities for employees
4:34pm
shares (the “Shares”) of common stock, $0.001 par value per share, of the Company, that may be issued pursuant to the Company’s 2020 Long-Term Incentive
S-8
b9ui1wf jl3
13 Mar 24
Registration of securities for employees
4:34pm
8-K
EX-99.1
z9w2 fepwz4d5b
13 Mar 24
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
6:14am
8-K
EX-99.1
9tqpmsje7fw68
25 Jan 24
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
7:01am
8-K
bu61idm5mrn
19 Jan 24
Liquidia Corporation Announces Updates to Operations Leadership
7:01am
8-K
EX-99.1
dvkycs9o
19 Jan 24
Liquidia Corporation Announces Updates to Operations Leadership
7:01am
8-K
EX-99.2
8rm6mdlbp
8 Jan 24
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
4:15pm
8-K
EX-99.1
v8an3v
8 Jan 24
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
4:15pm